Back to search results

Observational Study of Ocrelizumab and GLP-1 Agonists in Multiple Sclerosis

This observational study is looking at people with Multiple Sclerosis (MS) who are already taking Ocrelizumab and a GLP-1 agonist (a type of medication). The study wants to understand if taking a GLP-1 agonist, in addition to Ocrelizumab, affects how MS progresses. Researchers will track your disability over time, specifically looking at something called PIRA (progression independent of relapse activity). You can join if you are 18-70 years old, have MS, have a BMI of 24 or higher, and are already taking Ocrelizumab and a GLP-1 medication. The study aims to enroll 100 participants, but its current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 100 participants. It is not a randomized trial, meaning participants are not assigned to different treatment groups.
What's involved
You will participate for about 72 weeks, completing surveys every four weeks about your medications, health, and activities. You will also have Zoom interviews every 6 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, PIRA, is measured from enrollment to the end of the study at 72 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07207148

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Recruiting
Not specifiedAges 18–70Observational
Northwestern University
~100 participants
Updated 2026-03-17 on ClinicalTrials.gov
What's tested:GLP-1Ocrelizumab (US)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PIRA
Measured over From enrollment to the end of study at 72 weeks.

Conditions

Multiple Sclerosis

Explore related trials

Multiple SclerosisObesity

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Farrah J Mateen · PRINCIPAL_INVESTIGATOR · Northwestern University

Who to contact

Dylan Rice, BA
[email protected]
240-362-4800
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,
Adult age 18-70 years,
BMI \>=24.0 kg/m2,
Taken at least one dose of Ocrelizumab prior to study entry,
EDSS \<7.0,
Able to provide individual informed consent,
MRI available to confirm the diagnosis of MS.
Exposed to GLP-1 agonist treatment in the last 3 years or less, or starting on a GLP-1 agonist in the coming \<3 months,
Willing to report monthly patient-reported outcomes remotely or in-person.
Able to present for baseline and follow up in person,
Unexposed to a GLP-1 agonist in the past year,
Starting on a GLP-1 agonist in the next \<6 months,
Plan to be exposed to GLP-1 agonist for a minimum of 72 weeks following enrollment.

Exclusion

Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
Current clinical trial participant,
Unable to speak a language for which translation can be found in the hospital system,
Unclear documentation of MS diagnosis or prior or current MS treatment,
Relapse within the past 3 months,
Recent major surgical procedure in the past 6 months,
Exposure to steroids (systemic) within the past 3 months,
Not on Ocrelizumab in the past \>9 months,
Moribund status,
Underweight or experiencing protein malnutrition,
Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, dementia, etc.),
Unable to complete the study activities for any reason as deemed by the study investigator.

What this trial measures

  • PIRAFrom enrollment to the end of study at 72 weeks.

    The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.